Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system

被引:34
作者
Koh, Eng-Siew [1 ]
Nichol, Alan [2 ]
Millar, Barbara-Ann [1 ]
Menard, Cynthia [1 ]
Pond, Gregory [3 ]
Laperriere, Normand J. [1 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada
[2] Univ British Columbia, Dept Radiat Oncol, Vancouver, BC V5Z 1M9, Canada
[3] Princess Margaret Hosp, Dept Clin Study Coordinat & Biostat, Toronto, ON M4X 1K9, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 05期
关键词
hemangioblastoma; fractionated external beam radiotherapy;
D O I
10.1016/j.ijrobp.2007.05.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the clinical outcomes and toxicity in patients receiving fractionated external beam radiotherapy (EBRT) for hemangioblastoma of the central nervous system, treated at two Canadian radiation oncology institutions. Methods and Materials: Between January 1980 and December 2004, the data of all patients receiving EBRT for central nervous system hemangioblastoma were retrospectively reviewed. The patient, tumor, and treatment characteristics were collected and overall survival, disease-free survival, and EBRT-related toxicities assessed. Results: A total of 18 cases, 5 associated with von Hippel-Lindau disease (VHL) and 13 sporadic (non-VHL), with a total 31 lesions, were documented. These were located in the cerebellum in 20 and spinal cord in 8 patients. EBRT was delivered for recurrence in 12, adjuvantly for residual disease in 4, and definitively in 2. The EBRT schedules ranged from 50.0 to 55.8 Gy in 1.8-2.0-Gy daily fractions (n = 17), typically with parallel-opposed fields to the cerebellar target volumes and direct posterior fields for spinal disease. At a median follow-up of 5.1 years (range, 0.1-14.5), the 5-year OS rate was 69% (95% confidence interval [CI], 50-96%), decreasing to 30% (95% CI,10-87%) at 10 years. The disease-free survival rate at 5 and 10 years was 57% (95% CI, 37-87%) and 30% (95% CI, 11-83%), respectively. The outcomes differed according to VHL status. The 5-year OS rate was 100% for those with VHL compared with 55% (95% CI, 32-95%) for those with non-VHL disease (log-rank p = 0.003), and the 5-year disease-free survival rate was 80% (95% CI, 52-100%) with VHL compared with 48% (95% CI, 26-89%) without (log-rank p = 0.036). Conclusions: Fractionated EBRT has a role in the management of extensive intracranial and/or spinal cord disease, the adjuvant treatment of residual postoperative disease, and the treatment of recurrence. More favorable outcomes were reported for VHL-associated lesions than for sporadic cases. (c) 2007 Elsevier Inc.
引用
收藏
页码:1521 / 1526
页数:6
相关论文
共 24 条
[1]  
BOHLING T, 2000, PATHOLOGY GENETICS T, P223
[2]  
Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E
[3]   Hemangioblastomas of central nervous system: Molecular genetic analysis and clinical management [J].
Catapano, D ;
Muscarella, LA ;
Guarnieri, V ;
Zelante, L ;
D'Angelo, VA ;
D'Agruma, L .
NEUROSURGERY, 2005, 56 (06) :1215-1221
[4]   Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery [J].
Chang, SD ;
Meisel, JA ;
Hancock, SL ;
Martin, DP ;
McManus, M ;
Adler, JR .
NEUROSURGERY, 1998, 43 (01) :28-34
[5]   Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease [J].
Conway, JE ;
Chou, D ;
Clatterbuck, RE ;
Brem, H ;
Long, DM ;
Rigamonti, D .
NEUROSURGERY, 2001, 48 (01) :55-62
[6]   Risk of hemorrhage in hemangioblastomas of the central nervous system [J].
Gläsker, S ;
Van Velthoven, V .
NEUROSURGERY, 2005, 57 (01) :71-75
[7]   Stereotactic radiosurgery for hemangioblastomas of the brain [J].
Jawahar, A ;
Kondziolka, D ;
Garces, YI ;
Flickinger, JC ;
Pollock, BE ;
Lunsford, LD .
ACTA NEUROCHIRURGICA, 2000, 142 (06) :641-645
[8]   Role of VHL gene mutation in human cancer [J].
Kim, WY ;
Kaelin, WG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4991-5004
[9]   An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma [J].
Muscarella, Lucia Anna ;
Barbano, Raffaela ;
Augello, Bartolomeo ;
Formica, Vincenza ;
Micale, Lucia ;
Zelante, Leopoldo ;
D'Agruma, Leonardo ;
Merla, Giuseppe .
JOURNAL OF HUMAN GENETICS, 2007, 52 (06) :485-491
[10]   Long-term prognosis of haemangioblastoma of the CNS:: Impact of von Hippel-Lindau disease [J].
Niemelä, M ;
Lemeta, S ;
Summanen, P ;
Böhling, T ;
Sainio, M ;
Kere, J ;
Poussa, K ;
Sankila, R ;
Haapasalo, H ;
Kääriäinen, H ;
Pukkala, E ;
Jääskeläinen, J .
ACTA NEUROCHIRURGICA, 1999, 141 (11) :1147-1156